Global Excellence 2019

198 Acquisition International - Global Excellence 2019 20 Acquisit on International - Issue 8 2019 Interpace Diagnostics provides molecular tests and pathology services to physicians and hospitals for various types of cancer. Earlier this year, the company found success in AI’s Global Excellence Awards 2019 where they were selected as the Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Following this win, we caught up with Chief Commercial Officer, Greg Richard who kindly provided us with a glimpse into the award-winning services the team consistently delivers. ince their inception, Interpace Diagnostics has developed and commercialized molecular diagnostics tests for early detection of cancer in lesions where risk is uncertain by routine clinical methods. Today, Interpace Diagnostics currently has five marketed products for various indications: ThyGeNEXT, ThyraMIR, PancraGEN, RespriDx and BarreGEN. Going into further detail, Greg begins by informing us of the key qualities of each of these products and explaining what each one is used for. “ThyGeNEXT and ThyraMIR are used to determine whether or not a patient has risk factors for thyroid cancer; it helps assist physicians in making decisions regarding surgical intervention. PancraGEN, the company’s pancreatic cancer risk classifier, is performed on an integrated molecular pathology platform and assists physicians in identifying those patients with pancreatic cysts, solid lesions, and biliary strictures that are at risk of developing pancreatic or biliary cancer. PancraGEN has been used in over 40,000 patient samples and represents the largest data repository of molecular data on pancreatic cysts in the U.S. RespriDx is used to differentiate new lung tumors from those that represent metastasis from other organs to help drive therapeutic decision making. Finally, BarreGEN is used to evaluate mutational load in samples taken from the esophagus to Delivering Personalized Medicine Through Molecular Diagnostics and Innovation S identify patients that are at risk of progressing to esophageal cancer.” As for how these products are implemented and which industry experts the Interpace Diagnostics team approaches, Greg touches on the services and experiences each leader brings to the table and how they use the firm’s products. “For our Thyroid products, ThyGeNEXT and ThyraMIR, we call primarily on Endocrinologists, ENT’s, Pathologists, Endocrine Surgeons, and Otolaryngologists. We approach them directly via our own Commercial team; identifying them from industry trade conferences and specialty physician databases. “For pancreatic cancer, we call on Gastroenterologists and specifically those that perform Endoscopic Ultrasound Fine Needle Aspirates of the pancreas. These ‘Endoscopists’ are the primary source of our samples for molecular testing of pancreatic neoplasms. Additionally, we work closely with Pathologists who often perform routine first line tests prior to reflexing to molecular testing and PancraGEN. For BarreGEN, we essentially call on the same constituencies given that the procedure to collect the sample is similar to that used for PancraGEN. For RespriDX, we call on Thoracic Surgeons and Oncologists who focus on Lung cancer as a specialty within the overall oncology market.” Jun19373 Contact: Greg Richard Company: Interpace Diagnostics Address: 300 Interpace Parkway, Parsippany, NJ, 07054, United States Telephone: 201 749 2807 Web Address: www.interpacediagnostics.com “For our Thyroid products, ThyGeNEXT and ThyraMIR, we call primarily on Endocrinologists, ENT’s, Pathologists, Endocrine Surgeons, and Otolaryngologists. We approach them directly via our own Commercial team; identifying them from industry trade conferences and specialty physician databases.” Jun19373